
NovaBridge Biosciences (NBP) Stock Forecast & Price Target
NovaBridge Biosciences (NBP) Analyst Ratings
Bulls say
NovaBridge Biosciences is experiencing significant growth in research and development, with expenses rising from $41.1 million in FY24 to $62.9 million, reflecting increased investment in its pipeline of clinical programs. The potential for givastomig, a bispecific antibody aimed at treating gastric cancer and other malignancies, shows promise with improved gastrointestinal tolerability compared to competing therapies, positioning the product for substantial market share and translating into a multi-billion-dollar opportunity in the anti-VEGF market. Furthermore, FDA support for accelerated pathways enhances regulatory confidence and reduces timelines for market entry, with an upcoming registrational study set for as early as late 2026, contributing to a more favorable outlook for the company's stock.
Bears say
NovaBridge Biosciences is facing fundamental challenges in its operations, contributing to a negative outlook on its stock. The company reported a significant net loss from continuing operations of $88.3 million for FY2025, which was an increase from $49.7 million in FY2024, alongside an attributable loss per share that showed little improvement. Additionally, high rates of non-utilization of their therapies, despite expected biomarker positivity, coupled with complications in administration for candidates like zolbetuximab, indicate significant hurdles in market adoption and financial stability.
This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.
NovaBridge Biosciences (NBP) Analyst Forecast & Price Prediction
Start investing in NovaBridge Biosciences (NBP)
Order type
Buy in
Order amount
Est. shares
0 shares